NI201100209A - DERIVADOS DE 1H - IMIDAZOL [ 4, 5 - c ] QUINOLINONA - Google Patents

DERIVADOS DE 1H - IMIDAZOL [ 4, 5 - c ] QUINOLINONA

Info

Publication number
NI201100209A
NI201100209A NI201100209A NI201100209A NI201100209A NI 201100209 A NI201100209 A NI 201100209A NI 201100209 A NI201100209 A NI 201100209A NI 201100209 A NI201100209 A NI 201100209A NI 201100209 A NI201100209 A NI 201100209A
Authority
NI
Nicaragua
Prior art keywords
imidazo
quinolinone
treatment
derivatives
diseases
Prior art date
Application number
NI201100209A
Other languages
English (en)
Inventor
Furet Pascal
Stephan Kalthoff Frank
Ragot Christian
Mah Robert
Stauffer Frédéric
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201100209(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NI201100209A publication Critical patent/NI201100209A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere al uso de derivados de 1H - imidazo - [ 4, 5-c ] - quinolinona y de las sales de los mismos en el tratamiento de las enfermedades dependientes de la cinasa de proteína o de lípido y para la elaboración de las preparaciones farmacéuticas para el tratamiento de estas enfermedades; a los derivados de 1H - imidazo - [ 4, 5-c ] - quinolinona para utilizarse en el tratamiento de las enfermedades dependientes de la cinasa de proteína o de lípido; a un método para el tratamiento contra estas enfermedades, el cual comprende administrar los derivados de 1H - imidazo - [ 4, 5-c ] - quinolinona a un animal de sangre caliente, en especial a un ser humano; a las preparaciones farmacéuticas que comprenden un derivado de 1H - imidazo - [ 4, 5-c ] - quinolinona, en especial para el tratamiento de una enfermedad dependiente de la cinasa de proteína y/o de lípido; a los derivados 1H - imidazo - [ 4, 5-c ] - quinolinona novedosos; y a un proceso para la preparación de los derivados de 1H - imidazo - [ 4, 5-c ] - quinolinona novedosos.
NI201100209A 2009-06-04 2011-11-30 DERIVADOS DE 1H - IMIDAZOL [ 4, 5 - c ] QUINOLINONA NI201100209A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18414109P 2009-06-04 2009-06-04

Publications (1)

Publication Number Publication Date
NI201100209A true NI201100209A (es) 2012-02-02

Family

ID=42697442

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201100209A NI201100209A (es) 2009-06-04 2011-11-30 DERIVADOS DE 1H - IMIDAZOL [ 4, 5 - c ] QUINOLINONA

Country Status (30)

Country Link
US (2) US8476294B2 (es)
EP (1) EP2438064A1 (es)
JP (1) JP5596137B2 (es)
KR (1) KR101445458B1 (es)
CN (1) CN102574845B (es)
AR (1) AR076949A1 (es)
AU (1) AU2010255727B2 (es)
BR (1) BRPI1010621A2 (es)
CA (1) CA2763821A1 (es)
CL (1) CL2011003052A1 (es)
CO (1) CO6470887A2 (es)
CR (1) CR20110608A (es)
CU (1) CU24064B1 (es)
DO (1) DOP2011000373A (es)
EA (1) EA020715B1 (es)
EC (1) ECSP11011500A (es)
GE (1) GEP20156267B (es)
IL (1) IL216452A0 (es)
MA (1) MA33332B1 (es)
MX (1) MX2011012943A (es)
NI (1) NI201100209A (es)
NZ (1) NZ596487A (es)
PE (1) PE20120224A1 (es)
SG (1) SG176572A1 (es)
TN (1) TN2011000626A1 (es)
TW (1) TWI464168B (es)
UA (1) UA106074C2 (es)
UY (1) UY32682A (es)
WO (1) WO2010139731A1 (es)
ZA (1) ZA201108439B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CA2819955A1 (en) * 2010-12-06 2012-06-14 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
EP2781520B1 (en) * 2011-11-17 2016-05-04 Xuanzhu Pharma Co., Ltd. Three-ring pi3k and/or mtor inhibitor
WO2014141118A1 (en) * 2013-03-14 2014-09-18 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and uses thereof
MX2015014407A (es) 2013-04-15 2015-12-07 Du Pont Amidas fungicidas.
JP6576929B2 (ja) * 2013-09-11 2019-09-18 メルク パテント ゲーエムベーハー ヘテロ環化合物
WO2015043398A1 (zh) 2013-09-30 2015-04-02 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
US10989719B2 (en) * 2013-10-11 2021-04-27 National University Corporation Tokyo Medical And Dental University Methods for treating spinocerebellar ataxia type I using RPA1
CN104447740B (zh) * 2013-11-20 2017-02-22 北京富龙康泰生物技术有限公司 咪唑酮类衍生物、其药物组合物和用途
NO2714752T3 (es) 2014-05-08 2018-04-21
TWI675827B (zh) 2014-06-03 2019-11-01 瑞士商愛杜西亞製藥有限公司 吡唑化合物
WO2016155884A1 (de) * 2015-04-02 2016-10-06 Merck Patent Gmbh Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
BR112019007594A2 (pt) 2016-10-13 2019-07-02 Loyola University Of Chicago método para bloquear a transmissão do parasita da malária
BR112019011208A2 (pt) 2016-12-16 2019-10-15 Idorsia Pharmaceuticals Ltd combinação farmacêutica, composição farmacêutica, e, kit de partes.
JP6972144B2 (ja) 2017-02-06 2021-11-24 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd １−アリール−１−トリフルオロメチルシクロプロパンを合成するための新規な方法
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
BR112020012635A2 (pt) 2017-12-22 2020-12-01 Ravenna Pharmaceuticals, Inc. derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase
EP4142710B1 (en) 2020-09-21 2024-01-31 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
ATE400573T1 (de) 2003-11-21 2008-07-15 Novartis Pharma Gmbh 1h-imidazochinolinderivate als proteinkinaseinhibitoren
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
CN101056877B (zh) 2004-09-14 2010-06-09 诺华疫苗和诊断公司 咪唑并喹啉化合物
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR20080083270A (ko) 2005-11-04 2008-09-17 콜레이 파마시티컬 그룹, 인코포레이티드 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
AU2007323820B2 (en) 2006-11-20 2012-02-23 Novartis Ag Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl] -propionitrile
EP2129379B1 (en) * 2007-02-20 2019-04-10 Novartis AG Imidazoquinolines as dual lipid kinase and mtor inhibitors
PL2182948T3 (pl) * 2007-07-24 2013-07-31 Novartis Ag Zastosowanie imidazochinolin do leczenia chorób EGFR-zależnych albo chorób wykazujących nabytą oporność wobec środków ukierunkowanych na członków rodziny EGFR
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
CA2717948C (en) 2008-03-26 2016-09-06 Novartis Ag 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
US20110212053A1 (en) 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
EP2356120B1 (en) * 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions

Also Published As

Publication number Publication date
EA020715B1 (ru) 2015-01-30
JP5596137B2 (ja) 2014-09-24
KR101445458B1 (ko) 2014-10-07
CU20110221A7 (es) 2012-03-15
TWI464168B (zh) 2014-12-11
TN2011000626A1 (en) 2013-05-24
ZA201108439B (en) 2012-08-29
JP2012528828A (ja) 2012-11-15
EP2438064A1 (en) 2012-04-11
UA106074C2 (uk) 2014-07-25
MA33332B1 (fr) 2012-06-01
WO2010139731A1 (en) 2010-12-09
CR20110608A (es) 2012-01-16
SG176572A1 (en) 2012-01-30
CA2763821A1 (en) 2010-12-09
TW201102386A (en) 2011-01-16
CN102574845B (zh) 2015-09-02
CL2011003052A1 (es) 2012-08-31
CN102574845A (zh) 2012-07-11
IL216452A0 (en) 2012-01-31
ECSP11011500A (es) 2012-01-31
DOP2011000373A (es) 2011-12-31
PE20120224A1 (es) 2012-04-04
EA201101704A1 (ru) 2012-07-30
US8476294B2 (en) 2013-07-02
GEP20156267B (en) 2015-04-14
NZ596487A (en) 2012-11-30
AR076949A1 (es) 2011-07-20
US20100317657A1 (en) 2010-12-16
CO6470887A2 (es) 2012-06-29
AU2010255727B2 (en) 2013-02-28
MX2011012943A (es) 2012-01-27
UY32682A (es) 2011-01-31
AU2010255727A1 (en) 2011-12-08
BRPI1010621A2 (pt) 2016-06-21
KR20120034710A (ko) 2012-04-12
CU24064B1 (es) 2014-12-26
US20140005163A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
NI201100209A (es) DERIVADOS DE 1H - IMIDAZOL [ 4, 5 - c ] QUINOLINONA
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
BRPI0416796A (pt) compostos orgánicos
DK1509521T3 (da) 1H-Imidazol[4,5-c]quinolinderivater til behandling af proteinkinaseafhænige sygdomme
CY1117667T1 (el) 3,4-διαρυλπυραζολια ως αναστολεις κινασης πρωτεϊνης
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
BRPI0924460A2 (pt) composição farmacêutica para uso em oftalmologia médica e veterinária
MX2009008486A (es) Imidazoquinolinas como inhibidores dobles de cinasa de lipido y mtor.
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
NO20075136L (no) Nye liposompreparater
CU20100062A7 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
DOP2005000051A (es) Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos
AR104068A1 (es) Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
CY1110021T1 (el) ΔΙΑΡΩΜΑΤΙΚΕΣ ΕΝΩΣΕΙΣ ΟΙ ΟΠΟΙΕΣ ΕΝΕΡΓΟΠΟΙΟΥΝ ΥΠΟΔΟΧΕΙΣ ΤΟΥ ΤΥΠΟΥ PPARγ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΑΥΤΩΝ ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΣΤΗΝ ΚΟΣΜΗΤΙΚΗ Ή ΣΕ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ
ITMI20021866A1 (it) Preparazione farmaceutica in forma colloidale utile nella cura delle affezioni cutanee.
ECSP055984A (es) Derivados cicloalquilo que tienen grupos ácido carboxílico bioisostéricos, procesos para su preparación y su uso como composiciones farmacéuticas
MY159675A (en) Clerodane derivatives for modulation of leukotriene receptor activity and related diseases
CU23596A3 (es) Derivados de pirazol-quinazolina y proceso para su preparación
AR061355A1 (es) Preparaciones de combinacion que comprenden slv308 y l-dopa
AR061357A1 (es) Preparaciones de combinacion que comprenden bifeprunox y l- dopa